Sight Sciences has closed $31 million in Series D preferred stock financing in order to accelerate the growth of its Omni surgical system and TearCare system in the United States, according to a press release.
Funding was led by KCK Group, with participation from MidCap Financial.
Earlier this year, MidCap and Sight Sciences entered into a $25 million debt facility, bringing the total financing proceeds to $56 million.
“We could not be more thrilled than to have KCK as our lead growth equity investor and MidCap as our debt capital (Read more...)
Uncategorized